LucerastatAlternative Names: ACT-434964; OGT-923 - Actelion
Latest Information Update: 26 Jul 2016
At a glance
- Originator Actelion Pharmaceuticals
- Class Antihyperlipidaemics; Piperidines; Small molecules
- Mechanism of Action Glucosylceramide synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fabry's disease
- No development reported Lipid metabolism disorders